George Lloyd Sells 110,000 Shares of Royalty Pharma (NASDAQ:RPRX) Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP George Lloyd sold 110,000 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $39.77, for a total value of $4,374,700.00. Following the sale, the executive vice president owned 110,000 shares in the company, valued at $4,374,700. The trade was a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Royalty Pharma Stock Performance

Royalty Pharma stock traded up $0.58 during midday trading on Friday, reaching $39.73. 10,236,174 shares of the company’s stock were exchanged, compared to its average volume of 4,300,432. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.48 and a current ratio of 3.48. The stock’s 50-day simple moving average is $37.77 and its 200 day simple moving average is $36.31. The firm has a market cap of $22.93 billion, a price-to-earnings ratio of 30.10, a P/E/G ratio of 2.09 and a beta of 0.47. Royalty Pharma PLC has a 52 week low of $24.05 and a 52 week high of $41.24.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, topping analysts’ consensus estimates of $1.11 by $0.06. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. The firm had revenue of $609.29 million during the quarter, compared to analysts’ expectations of $765.01 million. On average, analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a dividend of $0.22 per share. This represents a $0.88 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date is Friday, November 14th. Royalty Pharma’s dividend payout ratio is presently 66.67%.

Hedge Funds Weigh In On Royalty Pharma

A number of hedge funds have recently bought and sold shares of RPRX. Cetera Investment Advisers bought a new position in shares of Royalty Pharma during the 1st quarter valued at $306,000. LPL Financial LLC increased its stake in shares of Royalty Pharma by 189.2% in the 1st quarter. LPL Financial LLC now owns 69,141 shares of the biopharmaceutical company’s stock worth $2,152,000 after purchasing an additional 45,236 shares in the last quarter. US Bancorp DE raised its holdings in Royalty Pharma by 41.0% in the 1st quarter. US Bancorp DE now owns 13,483 shares of the biopharmaceutical company’s stock worth $420,000 after purchasing an additional 3,918 shares during the period. PNC Financial Services Group Inc. lifted its position in Royalty Pharma by 7.3% during the first quarter. PNC Financial Services Group Inc. now owns 12,665 shares of the biopharmaceutical company’s stock valued at $394,000 after purchasing an additional 859 shares in the last quarter. Finally, Blair William & Co. IL bought a new stake in Royalty Pharma during the first quarter valued at about $212,000. Institutional investors own 54.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on RPRX. Wall Street Zen cut Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 28th. Morgan Stanley decreased their price target on shares of Royalty Pharma from $55.00 to $54.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. TD Cowen downgraded shares of Royalty Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 17th. Weiss Ratings lowered shares of Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. Finally, The Goldman Sachs Group started coverage on shares of Royalty Pharma in a report on Tuesday, September 30th. They set a “buy” rating and a $42.00 price target for the company. Three research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $46.00.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.